Literature DB >> 2230060

A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.

C C Ngen1, R Hassan.   

Abstract

Zopiclone, a cyclopyrrolone with hypnotic properties was compared with temazepam and placebo in the treatment of insomnia. After a week's washout period, suitable subjects were allocated at random to zopiclone 7.5 mg or temazepam 20 mg or placebo for 2 weeks. Measurements of psychomotor function using the Leed's psychomotor tester and letter cancellation were carried out on day 0, 7 and 14. Sleep latency, duration of sleep and number of times waking during the night were recorded on a sleep diary filled by the subjects nightly. Forty-four subjects completed the trial, 15 taking zopiclone, 16 taking temazepam and 10 taking placebo. Both zopiclone and temazepam had significant hypnotic properties when compared to placebo. Zopiclone increased total sleep time in both weeks of the trial while temazepam increased sleep time in the first week only. There was no significant deterioration in psychomotor performance at the end of both weeks for zopiclone. Critical flicker fusion was significantly increased in subjects on temazepam. There were no abnormalities for both zopiclone and temazepam subjects in the blood picture, renal profile, liver function, urine and ECG before and after the study. Zopiclone is an effective hypnotic comparable to temazepam.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230060     DOI: 10.1097/00004850-199007000-00001

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  10 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  R C Horton; M J Kendall
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

2.  Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures.

Authors:  S S Gilbert; C J van den Heuvel; D Dawson
Journal:  J Physiol       Date:  1999-02-01       Impact factor: 5.182

3.  Meta-analysis of benzodiazepine use in the treatment of insomnia.

Authors:  A M Holbrook; R Crowther; A Lotter; C Cheng; D King
Journal:  CMAJ       Date:  2000-01-25       Impact factor: 8.262

Review 4.  Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Authors:  S Noble; H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

5.  Sleep in the Elderly: Burden, Diagnosis, and Treatment.

Authors:  W Vaughn McCall
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

6.  Zopiclone: is it a pharmacologic agent for abuse?

Authors:  Nevio Cimolai
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

7.  The assessment and management of insomnia: an update.

Authors:  Andrew D Krystal; Aric A Prather; Liza H Ashbrook
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

Review 8.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 9.  Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 10.  A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

Authors:  G Hajak
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.228

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.